['\u200eHuman CD34 is a transmembrane glycoprotein which is expressed in human hematopoietic stem \u200ecells (HSCs) and the small-\u200evessel endothelial cells of a variety of tissues. CD34 plays a critical role as a \u200emarker for diagnosis \u200eand classification of leukemia. Anti CD34 antibodies are used for isolation and \u200epurification \u200eof HSCs from bone marrow, peripheral blood and cord blood.', 'To characterize a newly produced monoclonal antibody against a human CD34 peptide.', 'Anti CD34 monoclonal antibody (Clone 2C10-D3) was purified from mouse ascitic fluid and hybridoma cell culture supernatants by affinity chromatography and its immune reactivity was examined by ELISA. The purified antibody was further characterized using Western blot and flow cytometry on TF1 (Human Erythroblast) cell line.', '\u200eELISA experiment revealed that the antibody recognized CD34 peptide. Western \u200eblot analysis on TF1 \u200ecell lysate confirmed the reactivity of the antibody with a 42 KDa protein. Blocking the antibody with a saturating concentration of specific CD34 peptide resulted in loss of its activity with TF1 lysate in Western blot. The 2C10-D3 antibody reacted with TF1 cells in flow cytometry in a similar manner to a commercial anti CD34 monoclonal antibody.\u200e'] Does a novel mAb against a human CD34 peptide react with the native protein on CD34+ cells?